paclitaxel has been researched along with Carcinoma, Colloid in 82 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (2.44) | 18.2507 |
2000's | 34 (41.46) | 29.6817 |
2010's | 42 (51.22) | 24.3611 |
2020's | 4 (4.88) | 2.80 |
Authors | Studies |
---|---|
Chang, WH; Lai, WA; Lee, NR; Lee, WL; Shen, SH; Wang, PH; Yang, ST | 1 |
Chowdhury, S; Dickson, PN; Flatmark, K; Fleten, KG; Fournier, KF; Fowlkes, NW; Ito, I; Naini, ZA; Shen, JP; White, MG; Yousef, AMG | 1 |
Areepium, N; Liblab, S; Vusuratana, A | 1 |
Hatano, H; Imura, S; Johira, H; Kagajo, Y; Kashu, N; Kawata, N; Kimura, M; Tamura, S; Tomomatsu, M; Umeoka, T; Watanabe, R; Yunoki, S | 1 |
Asher, R; Beale, P; Friedlander, M; Kwok, JB; Lee, CK; Park, SB; Selle, F | 1 |
Kitawaki, J; Kokabu, T; Matsushima, H; Mori, T; Tarumi, Y; Tsuchiya, H | 1 |
Arakawa, A; Asai-Sato, M; Hongo, A; Inokuchi, Y; Kamiura, S; Kato, K; Komiyama, S; Matsumoto, T; Sugiyama, T; Tabata, T; Takano, H; Takeshima, N | 1 |
Al-Batran, SE; Alsina, M; Bang, YJ; Boku, N; Chung, HC; Conti, I; Evesque, L; Hallwachs, R; Hong, J; Lee, KW; Lichinitser, M; Moehler, MH; Park, SH; Ruiz, EY; Ryu, MH; Schenker, M; Taieb, J; Van Cutsem, E; Wyrwicz, L; Xiong, H | 1 |
Kim, S; Kim, SW; Kim, YT; Lee, J; Li, LY; Nam, EJ | 1 |
Igarashi, A; Imada, H; Saitou, Y; Suzuki, K; Takakura, S | 1 |
Cao, YC; Geng, M; Li, PF; Wang, L; Yin, YC | 1 |
Armstrong, DK; Birrer, MJ; Darcy, KM; Deloia, JA; Krivak, TC; Lesnock, JL; Thrall, MM; Tian, C; Zahn, C | 1 |
Abu-Rustum, NR; Andikyan, V; Barakat, RR; Chi, DS; Khoury-Collado, F; Konner, JA; O'Cearbhaill, RE; Sandadi, S; Sonoda, Y; Tew, WP | 1 |
Khunnarong, J; Manusirivithaya, S; Pataradool, K; Pitakkarnkul, S; Prutthiphongsit, W; Srijaipracharoen, S; Tangjitgamol, S; Thavaramara, T | 1 |
Enomoto, T; Fujita, M; Kimura, T; Miyatake, T; Nagamatsu, M; Nishio, Y; Tsutsui, T; Ueda, Y; Yamasaki, M; Yoshino, K | 1 |
Khemapech, N; Oranratanaphan, S | 1 |
Bookman, MA; Gatcliffe, TA; Java, JJ; Monk, BJ; Tewari, KS | 1 |
Ditto, A; Lorusso, D; Mancini, M; Ramondino, S; Raspagliesi, F; Zanaboni, F | 1 |
Baranowski, W; Bodnar, L; Cichowicz, M; Cierniak, S; Dąbek, A; Gąsowska-Bodnar, A; Jerzak, M; Kozłowski, W | 1 |
Aoyagi, S; Hata, H; Homma, E; Shimizu, H; Tsujiwaki, M | 1 |
Akman, T; Ellidokuz, H; Unal, OU; Yavuzsen, T; Yilmaz, AU | 1 |
Bertrand, M; Colombo, PE; Fabbro, M; Gutowski, M; Labaki, M; Mollevi, C; Mourregot, A; Quenet, F; Rouanet, P; Saint-Aubert, B | 1 |
Elbassuiony, MA; Elsayed, AM; Helal, AM; Ismail, YM; Moneer, MM; Nassar, HR; Zeeneldin, AA | 1 |
Ali, MS; El-Husseiny, K; Motawei, H | 1 |
Beriwal, S; Boisen, MM; Edwards, RP; Kelley, JL; Lesnock, JL; Richard, SD; Zorn, KK | 1 |
Cosio, S; Fanucchi, A; Gadducci, A; Lanfredini, N; Menichetti, A; Notarnicola, M | 1 |
Choi, DI; Im, KS; Kwon, YS | 1 |
Ahn, KJ; An, IS; An, S; Bae, S; Choi, YM; Kim, TJ; Lee, J; Lee, JH | 1 |
Konishi, I; Sugiyama, T | 1 |
Gao, M; Gao, YN; Jiang, GQ; Wang, W; Yan, X; Zheng, H | 1 |
Anan, K; Ishikawa, M; Iwakuma, N; Mitsuyama, S; Takamatsu, Y; Tamura, K; Umeda, S | 1 |
Jakobsen, A; Steffensen, KD; Waldstrøm, M | 1 |
Akamatsu, N; Aotani, E; Fujiwara, K; Kigawa, J; Miyagi, Y; Nagao, S; Noma, J; Numa, F; Okada, M | 1 |
Li, J; Li, Y; Lu, M; Shen, L; Xiao, Y; Zhang, J; Zhang, XD | 1 |
Bender, GP; Masellis, AM; Sielaff, TD | 1 |
Bell, J; Chan, JK; Fleming, GF; Herzog, TJ; Kapp, DS; Monk, BJ; Tian, C | 1 |
Bamias, A; Bournakis, E; Dimopoulos, MA; Haidopoulos, D; Lianos, E; Papadimitriou, C; Psaltopoulou, T; Rodolakis, A; Sotiropoulou, M; Vlahos, G | 1 |
Aletti, GD; Cliby, WA; Gallenberg, M; Hartmann, L; Long, HJ; Nordquist, D | 1 |
Alexandre, J; Cottu, P; Falandry, C; Floquet, A; Lebrun, D; Pujade-Lauraine, E; Ray-Coquard, I; Selle, F; Weber, B | 1 |
Park, WG; Pasricha, PJ | 1 |
Ishikawa, M; Komiyama, M; Komiyama, S; Kurahashi, T; Mikami, M; Tanaka, K; Udagawa, Y | 1 |
Jassem, J; Serkies, K; Węgrzynowicz, E | 1 |
Cibull, M; Cohn, DE; Gallion, HH; Gan, CM; Huh, WK; Richard, S | 1 |
Furuya, T; Hirowatari, H; Ito, K; Izawa, H; Karasawa, K; Mitsuhashi, N; Ozawa, S; Saito, M; Suzuki, T | 1 |
Bookman, MA | 1 |
Itamochi, H; Kigawa, J; Kitada, F; Minagawa, Y; Okada, M; Sato, S; Shimada, M | 1 |
Gallagher, CJ; Jeyarajah, A; Ledermann, JA; McCormack, M; McDonald, N; McNeish, I; Mould, T; Olaitan, A; Oram, D; Orphanos, G; Reynolds, K; Saha, A; Shepherd, J; Varughese, M; Wilson, P | 1 |
Brennan, D; Fennelly, D; Flannelly, G; Foley, M; Lenehan, P; Shireen, R | 1 |
Agnoletti, V; Amadori, A; Ansaloni, L; Catena, F; Cavaliere, D; Coccolini, F; De Iaco, P; Di Battista, M; Framarini, M; Gazzotti, F; Ghermandi, C; Kopf, B; Pinna, AD; Saponara, M; Tauceri, F; Vallicelli, C; Verdecchia, GM | 1 |
Baudrin, L; Cadranel, J; Coëtmeur, D; Duruisseaux, M; Monnet, I; Morère, JF; Morin, F; Moro-Sibilot, D; Mourlanette, P; Quoix, E; Soria, JC; Westeel, V; Wislez, M | 1 |
Li, M; Mao, N; Pan, L; Yin, J | 1 |
Antsaklis, A; Bamia, C; Bamias, A; Dimopoulos, MA; Haidopoulos, D; Kakoyianni, K; Kostouros, E; Rodolakis, A; Thomakos, N; Vlahos, G; Zagouri, F | 1 |
Matsui, H; Nagai, Y; Seki, K; Sekiya, S; Suzuka, K; Tanaka, N | 1 |
Atallah, D; Camatte, S; Castaigne, D; Duvillard, P; Joulie, F; Lhommé, C; Morice, P; Pautier, P; Rey, A; Thoury, A | 1 |
Bamias, A; Diakomanolis, E; Dimopoulos, AM; Markaki, S; Michalas, S; Milingos, S; Papadimitriou, C; Protopapas, A | 1 |
Daraï, E; Dormont, D; Madelenat, P; Zylberberg, B | 1 |
Bielawski, KP; Bosse, U; Schlotter, CM; Vogt, U | 1 |
Atabekoglu, C; Berker, B; Bilgin, T; Dunder, I | 1 |
Hasegawa, Y; Hayashi, N; Kato, Y; Tsukamoto, K; Wakita, T | 1 |
Aravantinos, G; Briasoulis, E; Dimopoulos, MA; Economopoulos, T; Efstathiou, E; Farmakis, D; Fountzilas, G; Kalofonos, HP; Pectasides, D; Salamalekis, E; Skarlos, D | 1 |
Akizuki, S; Andoh, M; Fujiwara, Y; Katsumata, N; Watanabe, T; Yamanaka, Y | 1 |
Aki, T; Asada, M; Enomoto, T; Ikegami, H; Ito, K; Kameda, T; Kuragaki, C; Mizutani, T; Murata, Y; Nagamatsu, M; Nakashima, R; Nishizaki, T; Otsuki, Y; Sugita, N; Ueda, Y; Ueno, Y; Wakimoto, A; Yamada, T; Yamazaki, M; Yoshino, K | 1 |
Akashi-Tanaka, S; Fukutomi, T; Iwamoto, E; Kinosita, T; Takasugi, M; Yamaguchi, J | 1 |
Aita, K; Goto, T; Matsubara, T; Nemoto, H; Sanada, Y; Sasaya, S; Shirahata, A; Yoshizawa, Y | 1 |
Ino, K; Kajiyama, H; Kikkawa, F; Nawa, A; Nomura, S; Shibata, K | 1 |
Aulitzky, WE; Fritz, P; Gerteis, A; Gutzeit, S; McClellan, M; Mürdter, TE; Simon, W; Sonnenberg, M; van der Kuip, H | 1 |
Canales Ugarte, S; Cassinello Espinosa, J | 1 |
Baki, M; Bodoky, G; Cseh, J; Csejtei, A; Csömör, S; Dank, M; Erfán, J; Esik, O; Faluhelyi, Z; Hernádi, Z; Izsó, J; Kammerer, K; Kásler, M; Magyar, T; Mayer, A; Megyery, E; Moskovits, K; Pécsi, L; Pikó, B; Pintér, T; Pulay, T; Ruzsa, A; Szánthó, A; Szántó, I; Szántó, J; Szucs, M; Tálos, Z; Thurzó, L | 1 |
Ahmetović, B; Fatusić, Z; Iljazović, E; Ljuca, D | 1 |
Hashimoto, H; Hirabayashi, T; Ishikawa, H; Ohi, S; Sugiyama, K; Tachibana, T; Takahashi, N; Yanaga, K | 1 |
Furukawa, T; Hirai, I; Hirai, Y; Kawago, M; Kiyoi, M; Kokawa, Y; Naito, K; Nakamura, R; Okamura, Y; Ota, F; Oura, S; Shimizu, Y; Tamaki, T; Tanino, H; Yoshimasu, T | 1 |
Maxwell, GL; McGuire, WP; Muggia, F; Rose, GS; Rose, PG; Rubin, SC; Sundborg, MJ; Tian, C; Winter, WE | 1 |
Colombo, N; Fossati, R; Fruscio, R; Garbi, A; Ieda', N; Lissoni, AA; Mangioni, C; Torri, V | 1 |
Brard, L; Charbonneau, N; Disilvestro, P; Dizon, DS; Granai, CO; Hughes, T; Legare, R; Lomme, M; Restivo, A; Weitzen, S | 1 |
Cao, YC; Fu, ZJ; Geng, M; Tai, YH; Wang, XY; Yin, YC | 1 |
Bauerschlag, DO; Hilpert, F; Jonat, W; Maass, N; Meinhold-Heerlein, I; Mundhenke, C; Roesel, F; Schem, C; Sturner, KH; Weigel, MT | 1 |
Chan, AT; Johnson, PJ; Leung, WT | 1 |
Ikeda, M; Kodama, S; Kudo, R; Nishiya, I; Noda, K; Nozawa, S; Taketani, Y; Tanaka, K; Terashima, Y; Yajima, A | 1 |
Blackburn, A; Buchanan, A; Cunningham, C; Edelman, G; Kirn, D; Maples, P; Nemunaitis, J; Netto, G; Olson, S; Randlev, B; Tong, A | 1 |
Keogh, P; Kingston, R; Leen, E; Sparkes, J; Stafford-Johnson, D | 1 |
Atkins, MB; DeWolf, WC; Gollob, JA; Upton, MP | 1 |
Hamaguchi, Y; Ichikawa, Y; Ishikawa, T; Kawano, N; Maegawa, J; Nakatani, Y; Ogino, I; Ohnishi, H; Shimada, H; Shimura, M | 1 |
3 review(s) available for paclitaxel and Carcinoma, Colloid
Article | Year |
---|---|
Emerging drugs for ovarian cancer.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Doxorubicin; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Infusions, Parenteral; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols | 2008 |
Paclitaxel and cisplatin chemotherapy for ovarian cancer during pregnancy: case report and review of the literature.
Topics: Adenocarcinoma, Mucinous; Adult; Antineoplastic Combined Chemotherapy Protocols; Appendectomy; Brain Neoplasms; Cesarean Section; Cisplatin; Fallopian Tubes; Fatal Outcome; Female; Humans; Infant, Newborn; Liver Neoplasms; Omentum; Ovarian Neoplasms; Ovariectomy; Paclitaxel; Pregnancy; Pregnancy Complications, Neoplastic | 2011 |
First-line chemotherapy in epithelial ovarian cancer.
Topics: Adenocarcinoma, Mucinous; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Cisplatin; Clinical Trials as Topic; Cystadenocarcinoma, Serous; Deoxycytidine; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Gemcitabine; Humans; Neoplasms, Glandular and Epithelial; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel; Poly(ADP-ribose) Polymerase Inhibitors; Receptors, Vascular Endothelial Growth Factor; Topotecan; Vascular Endothelial Growth Factor A | 2012 |
19 trial(s) available for paclitaxel and Carcinoma, Colloid
Article | Year |
---|---|
Clinical and genetic predictors of paclitaxel neurotoxicity based on patient- versus clinician-reported incidence and severity of neurotoxicity in the ICON7 trial.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Incidence; Middle Aged; Neoplasm Invasiveness; Neurotoxicity Syndromes; Outcome Assessment, Health Care; Ovarian Neoplasms; Paclitaxel; Patient Reported Outcome Measures; Physicians; Polymorphism, Single Nucleotide; Prognosis; Risk Factors; Severity of Illness Index; Surveys and Questionnaires; Survival Rate; Young Adult | 2017 |
Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Papillary; Carcinoma, Signet Ring Cell; Choice Behavior; Decision Support Techniques; Esophageal Neoplasms; Esophagogastric Junction; Female; Follow-Up Studies; Humans; International Agencies; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Practice Patterns, Physicians'; Prognosis; Stomach Neoplasms; Survival Rate; Young Adult | 2018 |
BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group Study.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Cisplatin; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; Injections, Intraperitoneal; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prognosis; Survival Rate | 2013 |
Treatment outcomes of paclitaxel for refractory or recurrent epithelial ovarian cancer patients in Thailand.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Cyclophosphamide; Cystadenocarcinoma, Serous; Deoxycytidine; Drug Resistance, Neoplasm; Endometrial Neoplasms; Etoposide; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prognosis; Survival Rate | 2013 |
A phase II study of combination chemotherapy using docetaxel and irinotecan for TC-refractory or TC-resistant ovarian carcinomas (GOGO-OV2 study) and for primary clear or mucinous ovarian carcinomas (GOGO-OV3 Study).
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Japan; Middle Aged; Ovarian Neoplasms; Paclitaxel; Prospective Studies; Taxoids | 2013 |
Characteristics and treatment outcomes of patients with malignant transformation arising from mature cystic teratoma of the ovary: experience at a single institution.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cell Transformation, Neoplastic; Cisplatin; Female; Fluorouracil; Follow-Up Studies; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate; Teratoma | 2013 |
Phase II trial on cisplatin-adriamycin-paclitaxel combination as neoadjuvant chemotherapy for locally advanced cervical adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cystadenocarcinoma, Serous; Doxorubicin; Female; Follow-Up Studies; Humans; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Paclitaxel; Prognosis; Survival Rate; Uterine Cervical Neoplasms; Young Adult | 2014 |
Second-line Intraperitoneal Platinum-based Therapy Leads to an Increase in Second-line Progression-free Survival for Epithelial Ovarian Cancer.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Infusions, Parenteral; Middle Aged; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate | 2016 |
Phase II study of intraperitoneal carboplatin with intravenous paclitaxel in patients with suboptimal residual epithelial ovarian or primary peritoneal cancer: a Sankai Gynecology Cancer Study Group Study.
Topics: Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Female; Humans; Infusions, Intravenous; Infusions, Parenteral; Maximum Tolerated Dose; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Survival Rate; Treatment Outcome | 2009 |
The potential benefit of 6 vs. 3 cycles of chemotherapy in subsets of women with early-stage high-risk epithelial ovarian cancer: an exploratory analysis of a Gynecologic Oncology Group study.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Endometrioid; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Risk Factors; Survival Rate | 2010 |
From randomized trial to practice: single institution experience using the GOG 172 i.p. chemotherapy regimen for ovarian cancer.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cross-Sectional Studies; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Injections, Intraperitoneal; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prospective Studies; Survival Rate; Treatment Outcome | 2010 |
Evaluation of extensive cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with advanced epithelial ovarian cancer.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Cystadenocarcinoma, Serous; Doxorubicin; Endometrial Neoplasms; Feasibility Studies; Female; Follow-Up Studies; Humans; Hyperthermia, Induced; Injections, Intraperitoneal; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Prospective Studies; Survival Rate | 2012 |
Chemotherapy effectiveness after first-line gefitinib treatment for advanced lepidic predominant adenocarcinoma (formerly advanced bronchioloalveolar carcinoma): exploratory analysis of the IFCT-0401 trial.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Adenocarcinoma, Mucinous; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Follow-Up Studies; Gefitinib; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Pemetrexed; Prognosis; Prospective Studies; Quinazolines; Salvage Therapy; Survival Rate | 2012 |
Are nodal metastases in ovarian cancer chemoresistant lesions? Analysis of nodal involvement in 105 patients treated with preoperative chemotherapy.
Topics: Adenocarcinoma, Mucinous; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Endometrioid; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Female; Humans; Lymph Node Excision; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Second-Look Surgery; Treatment Outcome | 2004 |
First-line intraperitoneal cisplatin-paclitaxel and intravenous ifosfamide in Stage IIIc ovarian epithelial cancer.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Endometrioid; Cisplatin; Cystadenocarcinoma, Serous; Disease-Free Survival; Drug Administration Schedule; Female; France; Humans; Ifosfamide; Infusions, Intravenous; Infusions, Parenteral; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Survival Analysis; Treatment Outcome | 2004 |
Preliminary experience with salvage weekly paclitaxel in women with advanced recurrent ovarian carcinoma.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adenocarcinoma, Papillary; Adult; Aged; Antineoplastic Agents, Phytogenic; CA-125 Antigen; Carcinoma, Endometrioid; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Radiography; Salvage Therapy; Survival Analysis; Treatment Outcome; Turkey | 2005 |
A phase II randomised clinical trial comparing cisplatin, paclitaxel and ifosfamide with cisplatin, paclitaxel and epirubicin in newly diagnosed advanced epithelial ovarian cancer: long-term survival analysis.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Endometrioid; Cisplatin; Cystadenocarcinoma, Serous; Epirubicin; Female; Follow-Up Studies; Humans; Ifosfamide; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Survival Rate; Time Factors | 2008 |
[A phase II study of BMS-181339 in patients with ovarian cancer. BMS-181339 Ovarian Cancer Study Group].
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Alopecia; Antineoplastic Agents, Phytogenic; Cystadenocarcinoma, Serous; Female; Fever; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Taxoids | 1994 |
Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adenoviridae; Adrenal Gland Neoplasms; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Carcinoma, Papillary; Carcinoma, Squamous Cell; Colonic Neoplasms; Feasibility Studies; Female; Genetic Therapy; Genetic Vectors; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Osteosarcoma; Paclitaxel; Thyroid Neoplasms | 2001 |
60 other study(ies) available for paclitaxel and Carcinoma, Colloid
Article | Year |
---|---|
Endometriosis-associated epithelial ovarian cancer is a more complicated disease than we suspected before.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Carcinoma, Endometrioid; Carcinoma, Ovarian Epithelial; Cisplatin; Endometriosis; Female; Humans; Laparotomy; Middle Aged; Ovarian Cysts; Ovarian Neoplasms; Paclitaxel; Treatment Outcome | 2021 |
Intraperitoneal Paclitaxel Is a Safe and Effective Therapeutic Strategy for Treating Mucinous Appendiceal Adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Animals; Female; Humans; Mice; Ovarian Neoplasms; Paclitaxel; Prospective Studies | 2023 |
ERCC1, XRCC1, and GSTP1 Polymorphisms and Treatment Outcomes of Advanced Epithelial Ovarian Cancer Patients Treated with Platinum-based Chemotherapy.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Cystadenocarcinoma, Serous; DNA-Binding Proteins; Drug Resistance, Neoplasm; Endometrial Neoplasms; Endonucleases; Female; Follow-Up Studies; Glutathione S-Transferase pi; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Polymorphism, Single Nucleotide; Prognosis; X-ray Repair Cross Complementing Protein 1 | 2020 |
[A Case of a Huge, Mixed-Type IPMC with Suspected Rupture of the Omental Bursa That Was Effectively Treated with Gemcitabine plus Nab-Paclitaxel].
Topics: Adenocarcinoma, Mucinous; Albumins; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Peritoneal Cavity; Positron Emission Tomography Computed Tomography | 2020 |
Long-term survival with bevacizumab in heavily pretreated and platinum-resistant mucinous ovarian cancer: A case report.
Topics: Adenocarcinoma, Mucinous; Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Disease-Free Survival; Female; Humans; Ovarian Neoplasms; Paclitaxel; Prognosis; Retreatment; Tomography, X-Ray Computed; Treatment Outcome | 2018 |
Bevacizumab combined with platinum-taxane chemotherapy as first-line treatment for advanced ovarian cancer: a prospective observational study of safety and efficacy in Japanese patients (JGOG3022 trial).
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Cystadenocarcinoma, Serous; Docetaxel; Endometrial Neoplasms; Female; Humans; Japan; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Prognosis; Prospective Studies; Safety; Survival Rate; Young Adult | 2019 |
Adenosine triphosphate-based chemotherapy response assay predicts long-term survival of primary epithelial ovarian cancer.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cystadenocarcinoma, Serous; Docetaxel; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate | 2019 |
Ovarian Mucinous Carcinoma with Mural Carcinosarcomatous Components in a Prepubertal Girl.
Topics: Adenocarcinoma, Mucinous; Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Combined Modality Therapy; Female; Humans; Magnetic Resonance Imaging; Ovarian Neoplasms; Paclitaxel | 2019 |
Correlation between chemosensitivity to anticancer drugs and telomerase reverse transcriptase mRNA expression in gastric cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adenocarcinoma, Papillary; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Signet Ring Cell; Case-Control Studies; Cell Differentiation; Cell Survival; Cisplatin; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Fluorouracil; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; In Situ Hybridization; Mitomycin; Neoplasm Grading; Paclitaxel; RNA, Messenger; Stomach Neoplasms; Telomerase; Tumor Cells, Cultured | 2013 |
Feasibility of adjuvant chemotherapy after pelvic exenteration for gynecologic malignancies.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Deoxycytidine; Endometrial Neoplasms; Feasibility Studies; Female; Follow-Up Studies; Gemcitabine; Genital Neoplasms, Female; Humans; Irinotecan; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Pelvic Exenteration; Prognosis; Retrospective Studies; Survival Rate; Topotecan | 2013 |
Chemotherapy-induced neutropenia as a biomarker of survival in advanced ovarian carcinoma: an exploratory study of the gynecologic oncology group.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cystadenocarcinoma, Serous; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Proportional Hazards Models; Treatment Outcome | 2014 |
Survivin expression as a prognostic factor in patients with epithelial ovarian cancer or primary peritoneal cancer treated with neoadjuvant chemotherapy.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Cisplatin; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; Inhibitor of Apoptosis Proteins; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Survival Rate; Survivin; Tumor Suppressor Protein p53 | 2014 |
Nanoparticle albumin-bound paclitaxel can be useful agent to advanced primary mucinous carcinoma of the skin.
Topics: Adenocarcinoma, Mucinous; Adult; Albumins; Antineoplastic Agents, Phytogenic; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Nanoparticles; Paclitaxel; Scalp; Skin Neoplasms | 2015 |
Intra-peritoneal cisplatin combined with intravenous paclitaxel in optimally debulked stage 3 ovarian cancer patients: an Izmir Oncology Group study.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Feasibility Studies; Female; Follow-Up Studies; Humans; Injections, Intraperitoneal; Injections, Intravenous; Middle Aged; Neoplasm Grading; Ovarian Neoplasms; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate | 2014 |
Impact of neoadjuvant chemotherapy cycles prior to interval surgery in patients with advanced epithelial ovarian cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Endometrioid; Carcinoma, Ovarian Epithelial; Carcinosarcoma; Cohort Studies; Cystadenocarcinoma, Serous; Cytoreduction Surgical Procedures; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Prognosis; Reoperation; Retrospective Studies; Treatment Outcome; Young Adult | 2014 |
Treatment Outcomes of Epithelial Ovarian Cancers Following Maximum Cytoreduction and Adjuvant Paclitaxel-Carboplatin Chemotherapy: Egyptian NCI Experience.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Combined Modality Therapy; Cystadenocarcinoma, Serous; Cytoreduction Surgical Procedures; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Grading; Neoplasm Staging; Ovarian Neoplasms; Ovariectomy; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate; Young Adult | 2015 |
Continuous Low-Dose Oral Cyclophosphamide and Methotrexate as Maintenance Therapy in Patients With Advanced Ovarian Carcinoma After Complete Clinical Response to Platinum and Paclitaxel Chemotherapy.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cyclophosphamide; Cystadenocarcinoma, Serous; Dose-Response Relationship, Drug; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Methotrexate; Middle Aged; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prognosis; Remission Induction; Survival Rate | 2016 |
Has serum CA 125 assay at the time of relapse a prognostic relevance for patients with recurrent ovarian carcinoma after primary cytoreduction and platinum- and paclitaxel-based chemotherapy?
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; CA-125 Antigen; Carboplatin; Carcinoma; Carcinoma, Endometrioid; Cohort Studies; Cytoreduction Surgical Procedures; Epirubicin; Female; Humans; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Paclitaxel; Prognosis; Retrospective Studies | 2016 |
Ovarian large cell neuroendocrine carcinoma in the youngest woman.
Topics: Adenocarcinoma, Mucinous; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Chemotherapy, Adjuvant; Cytoreduction Surgical Procedures; Fatal Outcome; Female; Humans; Hysterectomy; Multimodal Imaging; Ovarian Neoplasms; Ovariectomy; Paclitaxel; Positron-Emission Tomography; Salpingectomy; Tomography, X-Ray Computed; Treatment Failure | 2016 |
Musashi-2 is a novel regulator of paclitaxel sensitivity in ovarian cancer cells.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Antineoplastic Agents, Phytogenic; Apoptosis; Biomarkers, Tumor; Blotting, Western; Cell Proliferation; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Endometrial Neoplasms; Female; Gene Expression Regulation, Neoplastic; Humans; Immunoenzyme Techniques; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prognosis; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA-Binding Proteins; RNA, Messenger; Tumor Cells, Cultured | 2016 |
[Combined pegylated liposomal doxorubicin and carboplatin in the treatment of recurrent epithelial ovarian cancer].
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Doxorubicin; Drug Administration Schedule; Drug Evaluation; Female; Humans; Leukopenia; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Polyethylene Glycols; Retrospective Studies; Survival Analysis; Treatment Outcome | 2008 |
Paclitaxel as a first-line chemotherapy for Japanese women with advanced or recurrent breast cancer: a multi-institutional practice-based study by the Kyushu Breast Cancer Study Group (KBC-SG).
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adenocarcinoma, Scirrhous; Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Female; Humans; Japan; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prospective Studies; Receptor, ErbB-2; Salvage Therapy; Survival Rate; Treatment Outcome; Young Adult | 2010 |
The relationship of platinum resistance and ERCC1 protein expression in epithelial ovarian cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cystadenocarcinoma, Serous; DNA-Binding Proteins; Drug Resistance, Neoplasm; Endometrial Neoplasms; Endonucleases; Female; Humans; Immunoenzyme Techniques; Middle Aged; Ovarian Neoplasms; Paclitaxel; Prognosis; Survival Rate; Treatment Outcome | 2009 |
[Retrospective study on regimens of capecitabine-based chemotherapy in the treatment for advanced gastric cancer].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Signet Ring Cell; Cisplatin; Deoxycytidine; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Humans; Leukopenia; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Remission Induction; Retrospective Studies; Stomach Neoplasms; Survival Rate; Taxoids; Vomiting; Young Adult | 2009 |
Successful treatment of metastatic pancreatic adenocarcinoma with combination chemotherapy regimens.
Topics: Adenocarcinoma, Mucinous; Adult; Albumins; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biopsy, Fine-Needle; Capecitabine; Cisplatin; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gemcitabine; Humans; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Peritoneal Neoplasms; Taxoids; Tomography, X-Ray Computed; Treatment Outcome | 2009 |
Mucinous but not clear cell histology is associated with inferior survival in patients with advanced stage ovarian carcinoma treated with platinum-paclitaxel chemotherapy.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Prognosis | 2010 |
Mucinous advanced epithelial ovarian carcinoma: clinical presentation and sensitivity to platinum-paclitaxel-based chemotherapy, the GINECO experience.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cystadenocarcinoma, Mucinous; Databases, Factual; Disease Progression; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Platinum; Retrospective Studies; Young Adult | 2010 |
The conundrum of pancreatic cysts: are we finally moving the (EUS) needle?
Topics: Adenocarcinoma, Mucinous; Endosonography; Ethanol; Humans; Paclitaxel; Pancreatic Cyst; Pancreatic Neoplasms; Prevalence | 2011 |
Expression of TGFß1 and its receptors is associated with biological features of ovarian cancer and sensitivity to paclitaxel/carboplatin.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Endometrioid; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Humans; Immunoenzyme Techniques; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Protein Serine-Threonine Kinases; Receptor, Transforming Growth Factor-beta Type I; Receptor, Transforming Growth Factor-beta Type II; Receptors, Transforming Growth Factor beta; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Transforming Growth Factor beta1 | 2011 |
Consistency of in vitro chemoresponse assay results and population clinical response rates among women with endometrial carcinoma.
Topics: Adenocarcinoma, Mucinous; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cell Survival; Cisplatin; Cystadenocarcinoma, Serous; Doxorubicin; Endometrial Neoplasms; Female; Humans; In Vitro Techniques; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Survival Rate; Treatment Outcome; Tumor Cells, Cultured; United States | 2011 |
The role of chemoradiotherapy in patients with unresectable T4 breast tumors.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemoradiotherapy; Deoxycytidine; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prognosis; Remission Induction; Survival Rate; Taxoids | 2013 |
Feasibility study on biweekly paclitaxel treatment as maintenance chemotherapy in advanced müllerian carcinoma.
Topics: Adenocarcinoma; Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Endometrioid; Fallopian Tube Neoplasms; Feasibility Studies; Female; Humans; Maintenance Chemotherapy; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Treatment Outcome | 2012 |
Primary chemotherapy for inoperable ovarian, fallopian tube, or primary peritoneal cancer with or without delayed debulking surgery.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Survival Rate | 2012 |
Survival in women with ovarian cancer before and after the introduction of adjuvant paclitaxel; a 25-year, single institution review.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Chemotherapy, Adjuvant; Cystadenocarcinoma, Serous; Female; Humans; Neoplasm, Residual; Ovarian Neoplasms; Paclitaxel | 2012 |
Upregulation of phosphorylated cofilin 1 correlates with taxol resistance in human ovarian cancer in vitro and in vivo.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Agents, Phytogenic; Apoptosis; Biomarkers, Tumor; Blotting, Western; Carcinoma, Papillary; Carcinoma, Transitional Cell; Cell Proliferation; Cofilin 1; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Electrophoresis, Gel, Two-Dimensional; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; In Vitro Techniques; Middle Aged; Neoplasm Grading; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Phosphorylation; Prognosis; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tumor Cells, Cultured; Up-Regulation | 2013 |
Improved survival trends in platinum-resistant patients with advanced ovarian, fallopian or peritoneal cancer treated with first-line paclitaxel/platinum chemotherapy: the impact of novel agents.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Endometrial Neoplasms; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Survival Rate | 2013 |
Impact of maintenance chemotherapy on disease-free survival in patients with stage Ic and II epithelial ovarian cancer.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cystadenocarcinoma, Papillary; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Ifosfamide; Japan; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prognosis; Retrospective Studies | 2002 |
The prognostic significance of the immunohistochemical expression of p53, bcl-2, c-erb B-2 and cathepsin-D in ovarian cancer patients receiving platinum with cyclophosphamide or paclitaxel chemotherapy.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Endometrioid; Cathepsin D; Cyclophosphamide; Cystadenocarcinoma, Serous; Female; Humans; Immunohistochemistry; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Platinum; Predictive Value of Tests; Prognosis; Proto-Oncogene Proteins c-bcl-2; Receptor, ErbB-2; Survival Analysis; Tumor Suppressor Protein p53 | 2004 |
Breast tumour growth inhibition in vitro through the combination of cyclophosphamide/metotrexate/5-fluorouracil, epirubicin/cyclophosphamide, epirubicin/paclitaxel, and epirubicin/docetaxel with the bisphosphonates ibandronate and zoledronic acid.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Division; Cyclophosphamide; Diphosphonates; Docetaxel; Drug Synergism; Epirubicin; Female; Fluorouracil; Humans; Ibandronic Acid; Imidazoles; In Vitro Techniques; Methotrexate; Middle Aged; Neoplasm Invasiveness; Neoplasms, Ductal, Lobular, and Medullary; Paclitaxel; Taxoids; Zoledronic Acid | 2004 |
[Carcinoma of the urachus: a case report].
Topics: Adenocarcinoma, Mucinous; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Cystectomy; Drug Administration Schedule; Female; Humans; Hysterectomy; Lung Neoplasms; Paclitaxel; Urachus | 2005 |
Advanced stage mucinous epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Combined Modality Therapy; Female; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Survival Rate; Treatment Outcome | 2005 |
Weekly paclitaxel in patients with CAP-resistant advanced or recurrent endometrial carcinoma: a series of four patients.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adenocarcinoma, Papillary; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Endometrioid; Cisplatin; Cyclophosphamide; Cystadenocarcinoma, Serous; Doxorubicin; Drug Resistance, Neoplasm; Feasibility Studies; Female; Humans; Infusions, Intravenous; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Salvage Therapy; Survival Rate; Treatment Outcome | 2005 |
Prognostic significance of p53 mutation in suboptimally resected advanced ovarian carcinoma treated with the combination chemotherapy of paclitaxel and carboplatin.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Endometrioid; Cystadenocarcinoma, Serous; Female; Genes, p53; Humans; Microsatellite Repeats; Middle Aged; Ovarian Neoplasms; Paclitaxel; Prognosis; Prospective Studies; Survival Rate | 2006 |
A case of mucinous carcinoma of the breast that demonstrated a good pathological response to neoadjuvant chemotherapy despite a poor clinical response.
Topics: Adenocarcinoma, Mucinous; Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Neoadjuvant Therapy; Paclitaxel; Treatment Outcome | 2006 |
[Case study--an elderly patient with Stage IV advanced gastric cancer achieved good performance status (PS) without subjective symptoms for more than two years by chemotherapy].
Topics: Adenocarcinoma, Mucinous; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Combinations; Humans; Male; Neoplasm Staging; Oxonic Acid; Paclitaxel; Prognosis; Pyridines; Stomach Neoplasms; Tegafur | 2006 |
Clinical characteristics and prognosis of mucinous tumors of the ovary.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Female; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prognosis | 2006 |
Short term culture of breast cancer tissues to study the activity of the anticancer drug taxol in an intact tumor environment.
Topics: Adenocarcinoma, Mucinous; Adenosine Triphosphate; Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Carcinoma, Ductal, Breast; Cell Division; Cell Survival; DNA, Neoplasm; Drug Screening Assays, Antitumor; Female; Humans; Microscopy, Confocal; Microscopy, Fluorescence; Paclitaxel; Tumor Cells, Cultured | 2006 |
Cerebral and parotid metachronous metastases from an ovarian carcinoma.
Topics: Adenocarcinoma, Mucinous; Anticonvulsants; Carboplatin; Chemotherapy, Adjuvant; Combined Modality Therapy; Cranial Irradiation; Female; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Palliative Care; Parotid Neoplasms; Supratentorial Neoplasms; Topotecan | 2006 |
[The results of ovarian cancer therapy in the Hungarian Centers in 2002-2003].
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brenner Tumor; Carboplatin; Carcinoma; Carcinoma, Endometrioid; Chemotherapy, Adjuvant; Cystadenocarcinoma, Serous; Drug Administration Schedule; Female; Humans; Hungary; Middle Aged; Ovarian Neoplasms; Ovariectomy; Paclitaxel; Retrospective Studies; Treatment Outcome | 2006 |
Monitoring of chemotherapy successfulness of platina/taxol chemotherapy protocol by using determination of serum urokinase plasminogen activator (uPA) and soluble urokinase plasminogen activator receptor (suPAR) in patients with ovarian carcinoma FIGO II
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Dose-Response Relationship, Drug; Female; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prognosis; Prospective Studies; Receptors, Cell Surface; Receptors, Urokinase Plasminogen Activator; Treatment Outcome; Urokinase-Type Plasminogen Activator | 2007 |
Establishment and characterization of an IGSK-2 cell line derived from ascitic fluid of recurrent hCG and somatostatin secreted adenocarcinoma of the stomach.
Topics: Adenocarcinoma, Mucinous; Adult; Animals; Antigens, Tumor-Associated, Carbohydrate; Ascitic Fluid; Biomarkers, Tumor; Camptothecin; Carcinoembryonic Antigen; Cell Line, Tumor; Chorionic Gonadotropin; Cisplatin; Drug Screening Assays, Antitumor; Fluorouracil; Humans; Immunohistochemistry; Irinotecan; Male; Mice; Mice, Nude; Neoplasm Transplantation; Paclitaxel; Somatostatin; Stomach Neoplasms | 2007 |
In vitro evaluation of dose-response curve for paclitaxel in breast cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adenocarcinoma, Scirrhous; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Evaluation Studies as Topic; Female; Humans; Middle Aged; Neoplasm Invasiveness; Paclitaxel; Tumor Cells, Cultured | 2007 |
Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Endometrioid; Cisplatin; Cystadenocarcinoma, Serous; Female; Follow-Up Studies; Humans; Medical Records; Middle Aged; Neoplasm Staging; Neoplasm, Residual; Ovarian Neoplasms; Paclitaxel; Pleural Effusion, Malignant; Postoperative Complications; Prognosis; Randomized Controlled Trials as Topic; Retrospective Studies; Survival Rate | 2008 |
For women receiving chemotherapy for clinically apparent early ovarian cancer, is there a benefit to surgical staging?
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Endometrioid; Chemotherapy, Adjuvant; Cisplatin; Cohort Studies; Cyclophosphamide; Cystadenocarcinoma, Serous; Disease-Free Survival; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Survival Rate | 2008 |
[Anti-tumor effects of chemotherapeutic drugs on human gastric cancer cells in vitro and the relationship with expression of hTERT mRNA].
Topics: Adenocarcinoma, Mucinous; Adenocarcinoma, Papillary; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Signet Ring Cell; Cell Proliferation; Cisplatin; Doxorubicin; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Male; Middle Aged; Mitomycin; Paclitaxel; RNA, Messenger; Stomach Neoplasms; Telomerase | 2007 |
Novel treatment of ovarian cancer cell lines with Imatinib mesylate combined with Paclitaxel and Carboplatin leads to receptor-mediated antiproliferative effects.
Topics: Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Carboplatin; Carcinoma, Papillary; Cell Proliferation; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Female; Humans; Imatinib Mesylate; Immunoenzyme Techniques; Ovarian Neoplasms; Paclitaxel; Piperazines; Proto-Oncogene Proteins c-abl; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Platelet-Derived Growth Factor beta; RNA, Messenger; RNA, Neoplasm; Tissue Array Analysis; Tumor Cells, Cultured | 2008 |
Cerebrovascular event following taxol infusion.
Topics: Adenocarcinoma, Mucinous; Adult; Cerebral Infarction; Cerebrovascular Disorders; Chemotherapy, Adjuvant; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Ovarian Neoplasms; Paclitaxel; Salvage Therapy | 1994 |
Bone metastasis as the presenting complaint in ovarian carcinoma.
Topics: Adenocarcinoma, Mucinous; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Combined Modality Therapy; Fatal Outcome; Female; Humans; Ovarian Neoplasms; Paclitaxel; Shoulder Pain | 2001 |
Long-term remission in a patient with metastatic collecting duct carcinoma treated with taxol/carboplatin and surgery.
Topics: Adenocarcinoma, Mucinous; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Female; Humans; Kidney Neoplasms; Kidney Tubules, Distal; Neoplasm, Residual; Nephrectomy; Paclitaxel; Remission Induction | 2001 |
Locally advanced mucinous carcinoma of the breast with sudden growth acceleration: a case report.
Topics: Adenocarcinoma, Mucinous; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Disease Progression; Doxorubicin; Female; Humans; Mastectomy, Radical; Paclitaxel; Radiotherapy Dosage | 2002 |